The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

It is approved for administration as a single 5-second IV bolus. The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according to ...

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in acute ischaemic stroke (AIS). The drug, which has been authorised for use in ...

The tissue plasminogen activator ... Activase is administered as an IV bolus followed by a 60-minute infusion. TNKase is not a new treatment. It was approved in 2000 to reduce the risk of death ...

TNKase is delivered as a single five-second intravenous (IV) bolus, a faster and simpler administration ... leads to irreversible loss of nervous tissue, making immediate medical care crucial.

A clot-dissolving tissue plasminogen activator (tPA), tenecteplase ... Tenecteplase's updated label calls for IV administration as a single bolus over 5 seconds. Treatment should be initiated ...

Genentech’s new stroke drug is delivered as a single five-second intravenous (IV) bolus, whereas Activase ... It is a modified version of a tissue plasminogen activator and helps blood flow ...

INVINCIBLE-3 Study, and 25 patients have been screened Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several ...

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...